Demographics
Gender ( 14.9 ± 1.6 14.9 ± 1.6
Clinical history Duration (years) Primary cohort 8.5 ± 2.4 8.6 ± 2.3 Secondary cohort 15.5 ± 4.1 15.9 ± 4.0 HbA1c [% (mmol/mol)] 9.1 ± 1.5 (76.4 ± 16.9) 7.4 ± 1.1 (57.3 ± 12.0) † Mean DCCT HbA1c [% (mmol/mol)] 9.1 ± 1.3 (75.9 ± 13.9) 7.2 ± 0.9 (55.6 ± 10.1) † Insulin dose (U/kg/day) 0.66 ± 0.20 0.70 ± 0.25 † Regimen (%) CSII 1.6 41.0 † MDI 3.3 56.3 Standard 95.2 2.7 Systolic blood pressure (mmHg) 116.5 ± 11.9 116.6 ± 11.5 Diastolic blood pressure (mmHg) 74.3 ± 8.9 74.8 ± 8.7
Data are means ± SD, unless otherwise indicated. CSII=Continuous subcutaneous insulin infusion; MDI=Multiple daily injections *Difference between treatment groups is significant, P<0.01 †Difference between treatment groups is significant, P<0 CSII=Continuous subcutaneous insulin infusion; MDI=Multiple daily injections Time to first event using discrete time intervals during EDIC (regardless of prior DCCT hypoglycemia). Information about EDIC events was collected for the 3-month window prior to the annual visit. All covariates are fixed effects at DCCT closeout, except for the designated time-dependent covariates. The relative risk, presented per 10% decrease in HbA1c, is 0.9 β . CSII=Continuous subcutaneous insulin infusion; MDI=Multiple daily injections Time to any event using discrete time intervals during EDIC (regardless of prior DCCT hypoglycemia). Information about EDIC events was collected for the 3-month window prior to the annual visit. All covariates are fixed effects at DCCT closeout, except for the designated time-dependent covariates. The relative risk, presented per 10% decrease in HbA1c, is 0.9 β .
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